• Consensus Rating: Buy
  • Consensus Price Target: $97.50
  • Forecasted Upside: 17.22%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$83.18
▼ -4.58 (-5.22%)

This chart shows the closing price for HAE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Haemonetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HAE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HAE

Analyst Price Target is $97.50
▲ +17.22% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $97.50, with a high forecast of $110.00 and a low forecast of $84.00. The average price target represents a 17.22% upside from the last price of $83.18.

This chart shows the closing price for HAE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Haemonetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023MizuhoBoost TargetBuy$100.00 ➝ $110.00Low
1/6/2023Morgan StanleyLower TargetEqual Weight$90.00 ➝ $84.00Low
12/12/2022CitigroupBoost TargetNeutral$88.00 ➝ $92.00Low
11/8/2022Morgan StanleyBoost TargetEqual Weight$85.00 ➝ $90.00Low
11/8/2022Barrington ResearchBoost TargetOutperform$88.00 ➝ $94.00Low
11/8/2022Raymond JamesBoost TargetOutperform$88.00 ➝ $100.00Low
11/8/2022JMP SecuritiesBoost TargetMarket Outperform$90.00 ➝ $105.00Low
11/8/2022MizuhoBoost TargetBuy$90.00 ➝ $100.00Low
11/8/2022CitigroupBoost TargetNeutral$80.00 ➝ $88.00N/A
10/12/2022MizuhoInitiated CoverageBuy$90.00Low
10/11/2022Morgan StanleyBoost TargetEqual Weight$74.00 ➝ $85.00Low
10/5/2022CitigroupBoost Target$74.00 ➝ $80.00Low
8/15/2022CitigroupBoost Target$74.00N/A
8/11/2022Morgan StanleyBoost TargetEqual Weight$70.00 ➝ $74.00Low
8/11/2022JMP SecuritiesBoost TargetMarket Outperform$80.00 ➝ $90.00Low
8/11/2022Barrington ResearchBoost TargetOutperform$77.00 ➝ $88.00Low
8/11/2022Raymond JamesBoost TargetOutperform$76.00 ➝ $88.00Low
7/8/2022JMP SecuritiesReiterated RatingBuy$80.00N/A
7/1/2022Morgan StanleyBoost TargetEqual Weight$60.00 ➝ $70.00Low
7/1/2022Raymond JamesBoost TargetOutperform$63.00 ➝ $76.00Low
6/2/2022JMP SecuritiesReiterated RatingBuy$80.00High
5/11/2022Barrington ResearchBoost Target$71.00 ➝ $77.00High
2/9/2022Barrington ResearchReiterated RatingOutperformMedium
2/9/2022Raymond JamesLower TargetOutperform$70.00 ➝ $66.00Low
1/27/2022Needham & Company LLCDowngradeBuy ➝ HoldHigh
1/7/2022Morgan StanleyLower TargetEqual Weight$68.00 ➝ $60.00Low
12/15/2021CitigroupDowngradeBuy ➝ Neutral$75.00 ➝ $59.00High
11/10/2021JMP SecuritiesLower TargetOutperform$90.00 ➝ $80.00Medium
11/10/2021Raymond JamesLower TargetOutperform$75.00 ➝ $70.00Medium
6/29/2021Needham & Company LLCReiterated RatingBuy$86.00Low
6/17/2021CitigroupInitiated CoverageBuyHigh
5/20/2021JMP SecuritiesLower TargetMarket Outperform$110.00 ➝ $90.00Low
5/14/2021Jefferies Financial GroupLower TargetBuy$105.00 ➝ $85.00High
5/14/2021CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
5/14/2021Barrington ResearchLower TargetOutperform$91.00 ➝ $71.00High
5/14/2021Morgan StanleyLower TargetEqual Weight$83.00 ➝ $75.00High
5/14/2021JMP SecuritiesLower TargetOutperform$110.00 ➝ $90.00High
4/26/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$147.00 ➝ $83.00N/A
4/20/2021Barrington ResearchLower TargetOutperform$140.00 ➝ $91.00High
4/20/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$147.00 ➝ $83.00High
4/19/2021Needham & Company LLCLower TargetBuy$158.00 ➝ $108.00High
4/19/2021CJS SecuritiesDowngradeOutperform ➝ Market PerformHigh
2/12/2021Raymond JamesBoost TargetOutperform$145.00 ➝ $155.00Low
2/3/2021Morgan StanleyBoost TargetOverweight$139.00 ➝ $147.00Low
2/3/2021Raymond JamesBoost TargetOutperform$135.00 ➝ $145.00Low
2/3/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$140.00Low
1/21/2021JMP SecuritiesBoost Target$110.00 ➝ $140.00Medium
1/21/2021Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
1/20/2021Needham & Company LLCBoost TargetBuy$122.00 ➝ $142.00Medium
1/7/2021Raymond JamesBoost TargetOutperform$130.00 ➝ $135.00N/A
12/15/2020Morgan StanleyBoost TargetOverweight$110.00 ➝ $139.00Low
11/5/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$106.00High
11/2/2020Raymond JamesBoost TargetOutperform$100.00 ➝ $130.00Low
9/15/2020Barrington ResearchReiterated RatingHoldLow
9/8/2020Raymond JamesBoost TargetOutperform$93.00 ➝ $100.00Medium
8/5/2020Raymond JamesLower TargetOutperform$113.00 ➝ $93.00Low
8/4/2020Needham & Company LLCReiterated RatingBuy$119.00Low
7/8/2020Morgan StanleyLower TargetOverweight$138.00 ➝ $110.00Medium
7/1/2020Raymond JamesLower TargetOutperform$125.00 ➝ $113.00Low
5/29/2020Needham & Company LLCInitiated CoverageBuy$132.00Low
5/6/2020Raymond JamesLower TargetOutperform$130.00 ➝ $125.00High
5/6/2020Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
5/5/2020Needham & Company LLCLower TargetBuy$142.00 ➝ $132.00High
4/7/2020Raymond JamesLower TargetOutperform$150.00 ➝ $130.00High
3/31/2020CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
3/27/2020Morgan StanleyLower TargetOverweight$148.00 ➝ $138.00Low
2/5/2020Raymond JamesBoost TargetOutperform$145.00 ➝ $150.00High
2/4/2020Needham & Company LLCReiterated RatingBuy$142.00High
1/23/2020Raymond JamesLower TargetOutperform$150.00 ➝ $145.00High
1/10/2020Needham & Company LLCInitiated CoverageBuy$138.00Low
11/4/2019Barrington ResearchReiterated RatingBuy$141.00Low
8/7/2019Barrington ResearchReiterated RatingOutperform ➝ Outperform$116.00 ➝ $139.00Low
8/7/2019Morgan StanleyBoost TargetOverweight$128.00 ➝ $148.00Low
8/7/2019Raymond JamesBoost TargetOutperform$110.00 ➝ $150.00Low
8/7/2019JMP SecuritiesBoost TargetOutperform$145.00Low
8/2/2019Jefferies Financial GroupBoost TargetBuy$125.00 ➝ $140.00Low
5/14/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$110.00High
5/8/2019Barrington ResearchReiterated RatingOutperform ➝ Outperform$112.00 ➝ $116.00Low
2/6/2019Barrington ResearchBoost TargetOutperform ➝ Positive$112.00Low
10/5/2018Barrington ResearchReiterated RatingBuy$127.00High
8/9/2018Barrington ResearchBoost TargetOutperform$90.00 ➝ $118.00Low
8/8/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$100.00 ➝ $120.00Low
8/7/2018Jefferies Financial GroupReiterated RatingBuy$125.00Medium
6/14/2018Jefferies Financial GroupBoost TargetBuy ➝ Buy$95.00 ➝ $110.00Low
5/9/2018Barrington ResearchBoost TargetOutperform$90.00Low
5/9/2018Jefferies Financial GroupBoost TargetBuy$95.00Low
5/9/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$77.00 ➝ $100.00Low
2/7/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$74.00 ➝ $77.00High
2/7/2018Barrington ResearchReiterated RatingOutperform ➝ Outperform$57.00 ➝ $71.00High
2/7/2018JMP SecuritiesReiterated RatingOutperform$72.00High
2/7/2018Jefferies Financial GroupReiterated RatingBuy$80.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 4 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/11/2022
  • 8 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/8/2023
  • 11 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 11 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Haemonetics logo
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
Read More

Today's Range

Now: $83.18
Low: $82.09
High: $88.00

50 Day Range

MA: $82.33
Low: $72.75
High: $90.60

52 Week Range

Now: $83.18
Low: $48.67
High: $91.39

Volume

343,771 shs

Average Volume

480,891 shs

Market Capitalization

$4.21 billion

P/E Ratio

50.11

Dividend Yield

N/A

Beta

0.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Haemonetics?

The following equities research analysts have issued research reports on Haemonetics in the last twelve months: Barrington Research, Citigroup Inc., JMP Securities, Mizuho, Morgan Stanley, Raymond James, StockNews.com, and TheStreet.
View the latest analyst ratings for HAE.

What is the current price target for Haemonetics?

6 Wall Street analysts have set twelve-month price targets for Haemonetics in the last year. Their average twelve-month price target is $97.50, suggesting a possible upside of 17.2%. Mizuho has the highest price target set, predicting HAE will reach $110.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $84.00 for Haemonetics in the next year.
View the latest price targets for HAE.

What is the current consensus analyst rating for Haemonetics?

Haemonetics currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HAE will outperform the market and that investors should add to their positions of Haemonetics.
View the latest ratings for HAE.

What other companies compete with Haemonetics?

How do I contact Haemonetics' investor relations team?

Haemonetics' physical mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier's listed phone number is (781) 848-7100 and its investor relations email address is [email protected] The official website for Haemonetics is www.haemonetics.com. Learn More about contacing Haemonetics investor relations.